1月10日，恒瑞医药的一款抗PCSK9药物瑞卡西单抗获国家药监局批准上市，成为最新一款获批上市的国产靶向PCSK9的降脂药物。此前，已有6款PSCK9药物 ...

PCSK9抑制剂的使用正在为临床上难治性高胆固醇血症以及他汀类药物不耐受的患者群体开辟全新的治疗前景。 1月10日，恒瑞医药的一款抗PCSK9药物瑞 ...

近年来，一种新型降脂药物——PCSK9抑制剂进入临床应用，药物通过皮下注射的方式给药，具有长效性和便捷性的优势，可以每2周到每6个月注射一次 ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

Quevedo says. PCSK9 inhibitors are another medication. “PCSK9 inhibitors are drugs that block the PCSK9 protein, which ...

对此，近年来备受瞩目的PCSK9单抗类药物与他汀类药物的联合治疗方案应用越来越广泛，但在给药频率上仍存在一定局限性，患者需要每日服用他汀 ...

a safe and well-tolerated drug, for metastasis prevention in patients with inherited PCSK9 mutations.

Both types are effective at managing cholesterol, but researchers have uncovered some surprising side effects. Weight Gain: Some people taking statins might gain weight or body fat. Hormone Changes: ...